查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2010056

中枢神经系统药物市场：2026-2032年全球市场预测（依药物类别、剂型、目标患者、作用机制、治疗领域、通路、处方格式及销售模式划分）

Central Nervous System Drugs Market by Drug Class, Dosage Form, Patient Type, Mechanism Of Action, Therapeutic Area, Distribution Channel, Prescription Type, Sales Model - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，中枢神经系统药物市场价值将达到 248 亿美元，到 2026 年将成长至 269.3 亿美元，到 2032 年将达到 494.6 亿美元，复合年增长率为 10.36%。

主要市场统计数据
基准年 2025 248亿美元
预计年份：2026年 269.3亿美元
预测年份 2032 494.6亿美元
复合年增长率 (%) 10.36%

概述不断发展的中枢神经系统治疗市场，重点关注临床创新、患者需求和商业化驱动因素。

中枢神经系统（CNS）治疗领域正处于关键的转折点，这主要得益于科学进步、不断变化的监管预期以及医疗服务模式的变革。本执行摘要概述了现代CNS药物研发和商业化所涉及的广泛治疗类别、剂型、患者群体、作用机制和通路。透过阐明这些要素之间的相互作用，读者将更深入地了解临床创新如何满足未被满足的医疗需求，以及在哪些营运或政策限制下需要采取积极主动的措施。

神经科学、治疗技术和护理模式的进步如何汇聚起来，重塑中枢神经系统疗法的开发、获取和生命週期策略？

中枢神经系统疾病领域的变革性变化是由科学、技术和医疗保健系统三大领域的整合趋势所驱动的。分子神经科学的进步以及对突触和神经传导物质路径更深入的理解，正在催生新的监管靶点，从而催生出新型的在临床实验药物，并改善现有疗法的作用机制。以生物标记开发和分层试验设计为基础的精准医疗方法，使得针对异质性疾病的干预措施更具针对性，进而重塑了临床开发策略和监管互动。

了解不断变化的美国关税对中枢神经系统 (CNS) 治疗药物供应链的韧性、製造选择和通路经济的多方面影响。

近期美国主导的关税政策对中枢神经系统（CNS）治疗药物的供应链、製造业经济和策略采购决策施加了多重压力。依赖国际供应商提供活性成分、辅料或最终製剂的公司被迫重新评估其供应商组合，并更清楚地了解其多层级的供应关係，以确保供应的连续性。这种调整往往凸显了地理多元化和双重采购安排的重要性，这些安排能够有效吸收政策带来的成本和物流衝击。

基于药物类别、剂型、病患群体、作用机制、治疗领域、通路、处方状态和销售模式的详细细分，可以实现精准的策略调整。

详细的市场細項分析揭示了产品、患者、作用机制、治疗领域、分销管道、处方状态和销售模式等维度上的差异化机会和营运重点。依药物类别划分，市场涵盖镇痛药、抗忧郁剂、抗癫痫药、抗精神病药、抗焦虑药、中枢神经系统兴奋剂和催眠/镇静药。镇痛药类别进一步分为非阿片类镇痛药和阿片类镇痛药，每种镇痛药都有其独特的临床考虑和监管审查。抗癫痫药物根据其作用机制分为钙离子通道阻断剂、GABA增强剂、麸胺酸抑制剂和钠通道阻断剂，这些分类为临床前建模和临床终点选择提供了基础。抗精神病药分为非典型抗精神病药和典型抗精神病药，抗焦虑药则分为苯二氮平类和非苯二氮平治疗方法。中枢神经系统兴奋剂以安非他命和哌甲酯製剂为特征，而催眠药和镇静剂则包括巴比妥类药物、苯二氮平类药物和非苯二氮平类催眠药。了解这些药物类别之间的差异对于临床定位和监管风险评估至关重要。

美洲、欧洲、中东和非洲以及亚太地区的区域策略差异决定了监管策略、製造地和市场进入管道。

区域趋势对临床重点、监管互动、生产策略和商业性执行都有显着影响。在美洲，市场环境受支付主导的疗效预期、成熟的临床试验体係以及强调真实世界疗效的复杂报销结构的影响。临床开发往往优先考虑疗效比较终点和长期安全性数据，而商业策略则通常侧重于与医疗管理机构谈判、与专科药房合作以及与医生网络协作，以确保获得处方药资格。

创新公司、专业生物技术公司、非专利公司和生产合作伙伴为在中枢神经系统 (CNS) 治疗领域获得竞争优势而采取的策略策略和合作方式。

在中枢神经系统 (CNS) 领域营运的主要企业展现出多元化的策略方针，这反映了它们研发管线的成熟度、商业产品组合组成和营运实力。创新公司专注于独特的作用机制和新型给药平台以实现临床差异化，同时投资于真实世界数据 (REW) 项目和患者支持服务，以强化其价值提案。专业生技公司通常专注于具有高度未满足需求的特定适应症，并可能寻求合作和许可，以加速后期开发和商业化进程。

中枢神经系统治疗领域领导者面临的实际策略挑战：加强供应链韧性，使製剂创新与面向支付者的证据保持一致，并加速市场进入。

产业领导者应采取切实可行的优先事项，在科学抱负与实际可行性和市场现实之间取得平衡。首先，应透过多元化供应商关係，并对关键活性成分和复杂添加剂实施双重采购，来增强供应链韧性。基于情境的采购规划和合约保障措施可以减轻政策引发的干扰，并降低病患服务中断的风险。

本文概述了调查方法结合了对专家的初步访谈、对第二手资料的系统整合以及情景主导分析，以确保对中枢神经系统 (CNS) 市场获得可重复和可操作的见解。

本分析的调查方法结合了结构化的初步研究和全面的第二手资料，从而得出稳健且多角度的见解。初步研究活动包括对参与中枢神经系统（CNS）药物研发和分销的临床专业人员、监管专家、供应链经理和商业负责人进行深入检验。透过这些对话，我们获得了关于临床重点、证据预期和营运限制的定性背景信息，以指南战略决策。

透过整合强调全面临床差异化、营运韧性和与支付方需求一致的证据产生的策略挑战，我们确保永续进入中枢神经系统 (CNS) 市场。

整合科学进步、製剂创新、监管演变和分销管道变革等方面的洞见，揭示出一个核心主题：中枢神经系统治疗领域的成功需要整合策略，将临床差异化与卓越运营相结合。能够将新颖性机制转化为对患者有意义的疗效，同时确保供应连续性和与支付方协调一致的公司，将能够创造永续的价值。反之，即使拥有临床潜力，那些低估现代支付方和医疗服务提供者对营运和循证实践要求的公司，也可能面临市场准入壁垒。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 中枢神经系统药物市场：依药物类别划分

  • 止痛药
    • 非鸦片类镇痛药
    • 阿片类镇痛药
  • 抗忧郁症
  • 抗癫痫药物
    • 钙离子通道阻断剂
    • GABA增强剂
    • 麸胺酸抑制剂
    • 钠通道阻断剂
  • 抗精神病药物
    • 非典型
    • 典型的
  • 抗焦虑药物
    • 苯二氮平类药物
    • 非苯二氮平类药物
  • 中枢神经系统兴奋剂
    • 安非他命
    • 哌甲酯
  • 催眠药和镇静药
    • 巴比妥类药物
    • 苯二氮平类药物
    • 非苯二氮平类催眠药

第九章 中枢神经系统药物市场：依剂型划分

  • 胶囊
    • 缓释胶囊
    • 标准胶囊
  • 注射液
    • 肌肉内注射
    • IV
    • 皮下
  • 口服液
    • 悬浮液
    • 糖浆
  • 药片
    • 延迟释放片
    • 缓释片
    • 标准片剂
  • 经皮贴剂
    • 矩阵补丁
    • 水库补丁

第十章 中枢神经系统药物市场：依病患类型划分

  • 成人版
  • 老年人
  • 儿童

第十一章 中枢神经系统药物市场：依作用机制分类

  • 胆碱能
  • 多巴胺能
  • GABA能
  • 麸胺酸介导的
  • 去甲肾上腺素能
  • 血清素活性

第十二章 中枢神经系统药物市场：依治疗领域划分

  • ADHD
  • 阿兹海默症
  • 焦虑症
  • 忧郁症
  • 癫痫
  • 失眠
  • 偏头痛
  • 疼痛
  • 帕金森氏症
  • 思觉失调症

第十三章 中枢神经系统药物市场：依分销管道划分

  • 医院药房
  • 网路药房
  • 零售药房

第十四章 中枢神经系统药物市场：依处方类型划分

  • 非处方药
  • 处方药

第十五章 中枢神经系统药物市场：依销售模式划分

  • 品牌商品
  • 非专利的

第十六章 中枢神经系统药物市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十七章 中枢神经系统药物市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十八章 中枢神经系统药物市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十九章：美国中枢神经系统药物市场

第二十章：中国中枢神经系统药物市场

第21章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc
  • Allergan plc
  • Amgen Inc
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • H. Lundbeck A/S
  • Johnson & Johnson Services, Inc
  • Merck & Co., Inc
  • Neurocrine Biosciences, Inc
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd
  • Pfizer Inc
  • Sanofi SA
  • Takeda Pharmaceutical Company Ltd
  • Teva Pharmaceutical Industries Ltd
  • UCB SA
Product Code: MRR-434CCDA05199

The Central Nervous System Drugs Market was valued at USD 24.80 billion in 2025 and is projected to grow to USD 26.93 billion in 2026, with a CAGR of 10.36%, reaching USD 49.46 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 24.80 billion
Estimated Year [2026] USD 26.93 billion
Forecast Year [2032] USD 49.46 billion
CAGR (%) 10.36%

A concise orientation to the evolving central nervous system therapeutics landscape emphasizing clinical innovation, patient needs, and commercialization drivers

The central nervous system therapeutics domain is at a pivotal juncture, shaped by converging scientific advances, evolving regulatory expectations, and shifting patterns of care delivery. This executive summary provides a focused orientation to the broad set of therapeutic classes, dosage formats, patient populations, mechanisms of action, and distribution pathways that define contemporary CNS drug development and commercialization. By clarifying how these elements interact, readers can better understand where clinical innovation aligns with unmet needs, and where operational or policy-driven constraints require proactive mitigation.

Across the spectrum from analgesics and antidepressants to antiepileptics and antipsychotics, development strategies increasingly prioritize precision, tolerability, and long-term safety. New formulations and delivery technologies seek to improve adherence and reduce systemic adverse effects, while digital health adjuncts are positioning themselves as complementary solutions for symptom tracking and behavioral interventions. Concurrently, payer expectations and real-world evidence requirements are raising the bar for demonstrating comparative effectiveness and value, influencing both clinical development plans and commercialization timelines.

The central nervous system area demands an integrated view that spans scientific mechanism, patient segmentation, and channel dynamics. This introduction sets the stage for a deeper analysis of the structural shifts reshaping the landscape, the policy changes that are altering cost and supply considerations, and the segmentation insights that inform targeted product and market strategies.

How converging advances in neuroscience, delivery technologies, and care models are reshaping development, access, and lifecycle strategies in CNS therapeutics

Transformative shifts in the central nervous system field are being driven by convergent trends across science, technology, and health systems. Advances in molecular neuroscience and an improved understanding of synaptic and neurotransmitter pathways have created novel targets for modulation, prompting new classes of investigational agents and mechanistic refinements of existing therapies. Precision approaches-rooted in biomarker development and stratified trial designs-are enabling more targeted interventions for heterogeneous conditions, and this, in turn, is reshaping clinical development strategies and regulatory engagement.

Parallel to scientific innovation, delivery science and formulation engineering are altering routes to patient access. Extended-release platforms, novel transdermal systems, and parenteral formats designed for sustained delivery are being prioritized to improve adherence and to differentiate products in crowded therapeutic categories. Digital therapeutics and connected adherence tools are increasingly integrated with drug development programs to demonstrate patient-centric outcomes and to support reimbursement discussions. These adjuncts also create opportunities for lifecycle management and new revenue models that extend beyond traditional pharmaceutical sales.

Health system evolution is redefining commercialization channels. Telemedicine expansion, remote monitoring, and pharmacy delivery models are changing how patients obtain CNS therapies and how clinicians manage long-term conditions. At the same time, regulatory frameworks and payer expectations for real-world evidence are encouraging manufacturers to plan post-authorization evidence generation earlier in development. The combined effect of these shifts is a landscape in which scientific novelty, delivery innovation, and evidence generation must be orchestrated to succeed commercially and clinically.

Understanding the multifaceted influence of evolving U.S. tariffs on supply chain resilience, manufacturing choices, and channel economics for CNS therapeutics

Recent tariff policies originating from the United States have exerted multi-dimensional pressure on CNS drug supply chains, manufacturing economics, and strategic sourcing decisions. Companies that rely on international suppliers for active pharmaceutical ingredients, excipients, or finished dosage forms have needed to reassess vendor portfolios and to increase visibility into tiered supply relationships to maintain continuity of supply. This recalibration often elevates the importance of geographic diversification and of dual sourcing arrangements that can absorb policy-induced cost and logistical shocks.

Tariff-driven cost increases affect different segments of the CNS value chain in distinct ways. Innovator companies with differentiated therapeutic offerings may be better positioned to negotiate price adjustments or to absorb marginal cost increases through value arguments, whereas generic manufacturers operating in thin-margin categories face heightened pressure to optimize production efficiency and to secure low-cost raw materials. Deliberations around onshoring certain manufacturing activities or expanding regional production capacity are now routine elements of portfolio planning conversations, especially for dosage forms that demand complex manufacturing capabilities such as extended-release oral solids or specialized injectable solutions.

In response to tariff-related disruptions, commercial teams have also scrutinized distribution strategies. Shifts in channel economics can influence decisions about the balance between hospital pharmacies, retail pharmacy networks, and online pharmacy partnerships. Moreover, regulatory and payer landscapes can compound tariff effects by influencing reimbursement dynamics and procurement sourcing policies. The net result is a heightened emphasis on scenario planning, clearer contractual protections with suppliers, and more robust supply chain governance to protect both continuity of care and commercial viability.

Deep segmentation-driven insights across drug class, formulation, patient cohort, mechanism, therapeutic area, channel, prescription status, and sales model for precise strategic alignment

A granular view of segmentation reveals differentiated opportunities and operational priorities across product, patient, mechanism, therapeutic area, channel, prescription status, and sales model dimensions. Within drug classes, the market spans analgesic, antidepressant, antiepileptic, antipsychotic, anxiolytic, CNS stimulant, and hypnotic and sedative categories. The analgesic category further divides into non-opioid and opioid analgesics, each with distinct clinical considerations and regulatory scrutiny. Antiepileptic agents cluster by mechanism into calcium channel blockers, GABA enhancers, glutamate inhibitors, and sodium channel blockers, which informs both preclinical modeling and clinical endpoint selection. Antipsychotic compounds bifurcate into atypical and typical classes, while anxiolytics are differentiated into benzodiazepine and non-benzodiazepine treatments. CNS stimulants are characterized by amphetamines and methylphenidate variants, and hypnotic and sedative modalities include barbiturates, benzodiazepines, and non-benzodiazepine hypnotics. Understanding these class-level distinctions is critical for clinical positioning and regulatory risk assessment.

Dosage form segmentation spans capsule, injectable solution, oral solution, tablet, and transdermal patch presentations. Capsules may be standard or extended-release, and injectable solutions may be administered intramuscularly, intravenously, or subcutaneously, each route carrying unique clinical use cases and supply chain implications. Oral solutions are typically provided as suspensions or syrups, whereas tablets can be formulated as delayed-release, extended-release, or standard immediate-release types. Transdermal patches are engineered as matrix or reservoir systems, and they represent an important route for improving adherence and steady-state exposure in select indications. These dosage characteristics influence development complexity, regulatory dossiers, manufacturing investments, and commercial messaging.

Patient type segmentation identifies adult, geriatric, and pediatric populations, underscoring the need for age-appropriate formulations, dosing strategies, and safety monitoring. Mechanism of action segmentation highlights cholinergic, dopaminergic, GABAergic, glutamatergic, noradrenergic, and serotonergic approaches, providing a framework for biomarker selection and for therapeutic differentiation. Therapeutic area segmentation includes ADHD, Alzheimer's disease, anxiety, depression, epilepsy, insomnia, migraine, pain, Parkinson's disease, and schizophrenia; each area brings distinct endpoints, comorbidity profiles, and stakeholder expectations that shape both clinical development and market access pathways. Distribution channel segmentation-hospital pharmacy, online pharmacy, and retail pharmacy-affects fulfillment strategies, patient support programs, and reimbursement alignment. Prescription type segmentation differentiates over-the-counter from prescription products, which has implications for regulatory classification and consumer marketing. Sales model segmentation separates branded from generic offerings, determining the intensity of promotional activity, pricing flexibility, and lifecycle extension tactics. Together, these segmentation lenses create a matrix that decision-makers can use to align R&D priorities, manufacturing investments, and commercial tactics with distinct patient and market needs.

Regional strategic differences across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine regulatory strategy, manufacturing location, and market access pathways

Regional dynamics materially influence clinical priorities, regulatory engagement, manufacturing strategy, and commercial execution. In the Americas, the market environment is shaped by payer-driven outcomes expectations, a mature clinical trial ecosystem, and a complex reimbursement architecture that privileges demonstrable real-world effectiveness. Clinical development tends to emphasize comparative effectiveness endpoints and long-term safety data, while commercial strategies often concentrate on managed care negotiations, specialty pharmacy partnerships, and physician network engagement to secure formulary placement.

In Europe, Middle East & Africa, regulatory diversity and heterogeneous procurement systems create a mosaic of access considerations. Countries within this wider region exhibit varying degrees of centralized assessment versus decentralized procurement, and manufacturers need differentiated market access dossiers to address national HTA processes and local pricing negotiations. In addition, regional manufacturing hubs and strategic partnerships with contract manufacturers can be instrumental for market entry and for managing cross-border supply chain risks. Clinical development plans often incorporate multi-jurisdictional requirements early to streamline approvals and reimbursement discussions.

In Asia-Pacific, strong growth in clinical trial activity, rising investment in biomanufacturing, and increasing digital health adoption are notable. Local regulatory authorities are enhancing capabilities and streamlining pathways for innovative therapies, and governments are investing in domestic production capacity for critical therapeutics. Distribution channel innovation-especially rapid expansion of online pharmacy models and telehealth services-shapes access pathways for chronic CNS conditions. Together, these regional characteristics should inform manufacturing location decisions, regulatory engagement sequencing, and tailored commercial models that reflect payers, prescribers, and patient behavior in each geography.

Strategic playbooks and collaborative approaches adopted by innovators, specialty biotechs, generics, and manufacturing partners to gain competitive advantage in CNS therapies

Key companies operating in the central nervous system space demonstrate a range of strategic postures that reflect their pipeline maturity, commercial portfolio composition, and operational strengths. Innovator firms emphasize differentiated mechanisms of action and novel delivery platforms to establish clinical differentiation, while also investing in real-world evidence programs and patient support services to substantiate value propositions. Specialty biotechs often focus on narrow indications with high unmet need and may pursue partnerships or licensing to accelerate late-stage development and commercialization.

Generic and contract manufacturing organizations are concentrating on scale, cost optimization, and flexible manufacturing capabilities to meet demand for established formulation types and to support rapid fill-and-finish needs. These players also explore opportunities to manufacture complex modified-release products and transdermal systems as a route to capture higher-value manufacturing contracts. At the intersection of therapeutic and technology innovation, digital health companies and platform providers are collaborating with pharmaceutical firms to integrate adherence tracking, remote monitoring, and outcome measurement into product value chains, facilitating new evidence generation pathways that support reimbursement dialogues.

Across company types, effective strategies include targeted alliance formation with academic centers and clinical networks to access specialized patient populations, early engagement with regulatory authorities to clarify evidentiary expectations, and disciplined lifecycle management to extend product relevance through formulation improvements or label expansions. Firms that align R&D priorities with pragmatic commercial execution plans and robust supply chain governance are best positioned to navigate the complexity of CNS markets.

Practical strategic imperatives for leaders to bolster supply chain resilience, align formulation innovation with payer evidence, and accelerate market access in CNS therapeutics

Industry leaders should pursue a set of actionable priorities that balance scientific ambition with operational pragmatism and market realism. First, strengthen supply chain resilience by diversifying supplier relationships and incorporating dual sourcing for critical active ingredients and complex excipients. Scenario-based procurement planning and contractual protections can mitigate policy-driven disruptions and reduce the risk of service interruptions for patients.

Second, invest strategically in dosage form innovation that aligns with adherence and safety imperatives. Extended-release formulations, transdermal systems, and patient-friendly oral solutions can differentiate products in competitive categories and support improved clinical outcomes. Product teams should align these formulation choices with payer evidence needs and with pragmatic manufacturing pathways that control complexity and time to market.

Third, design development programs that integrate real-world evidence generation from the outset. Early planning for pragmatic trials, registry-based outcome collection, and post-authorization safety studies can accelerate reimbursement discussions and strengthen clinical value claims. Fourth, prioritize targeted market access strategies by engaging payers and health technology assessment bodies early to understand evidence thresholds and to co-design outcome measures that matter for coverage decisions.

Fifth, pursue partnerships across the ecosystem-including academic centers, digital health firms, and experienced contract development organizations-to fill capability gaps and to accelerate time-to-market. Finally, execute a differentiated commercial strategy that tailors messaging and channel mix to patient segments and provider workflows, leveraging specialty pharmacy capabilities where appropriate and embracing online pharmacy channels to meet evolving patient preferences.

Methodological overview combining primary expert interviews, systematic secondary synthesis, and scenario-driven analysis to ensure reproducible and actionable CNS market insights

The research methodology behind this analysis combines structured primary inquiry with comprehensive secondary synthesis to produce robust, triangulated insights. Primary research activities included in-depth interviews with clinical experts, regulatory specialists, supply chain managers, and commercial leaders involved in central nervous system drug development and distribution. These conversations provided qualitative context around clinical priorities, evidentiary expectations, and operational constraints that inform strategic decision-making.

Secondary research involved systematic review of peer-reviewed literature, clinical trial registries, regulatory guidance, public company disclosures, and industry conference materials. Data were cross-validated across multiple public and proprietary sources to reduce bias and to ensure consistency of interpretation. The study also integrated case-based analyses of recent product launches and regulatory interactions to surface practical lessons that are relevant across therapeutic classes and dosage forms.

Analytic techniques included thematic synthesis to identify cross-cutting trends, scenario planning to explore the implications of policy and supply chain shifts, and gap analysis to expose unmet clinical and commercial needs. Quality control measures included peer review by subject matter experts and reconciliation of divergent perspectives through iterative validation. The methodology emphasizes transparency, reproducibility, and pragmatic interpretation so that findings can be directly applied to portfolio planning, due diligence, and market entry strategy.

Synthesis of strategic imperatives emphasizing integrated clinical differentiation, operational resilience, and payer-aligned evidence generation to secure durable CNS market access

The combined insights from scientific advances, formulation innovation, regulatory evolution, and distribution transformation point to a central theme: success in the central nervous system therapeutics domain requires integrated strategy that aligns clinical differentiation with operational excellence. Companies that can translate mechanistic novelty into patient-relevant outcomes while ensuring supply continuity and payer alignment stand to create sustainable value. Conversely, firms that underestimate the operational or evidence-generation demands of contemporary payers and providers may face access barriers despite clinical promise.

Strategic clarity-rooted in segmentation-driven planning, regional nuance, and a rigorous appreciation of supply chain and policy dynamics-enables stakeholders to prioritize investments and to design partnerships that accelerate clinical and commercial milestones. The recommendations in this summary are intended to guide deliberative action: fortify supply networks, select formulation and delivery modalities that improve adherence and differentiate products, engage payers and regulators early, and integrate real-world evidence into commercialization plans. By adopting these practices, teams can better navigate the complexity of CNS markets and position novel and established therapies for durable clinical and commercial impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Central Nervous System Drugs Market, by Drug Class

  • 8.1. Analgesic
    • 8.1.1. Non-Opioid Analgesic
    • 8.1.2. Opioid Analgesic
  • 8.2. Antidepressant
  • 8.3. Antiepileptic
    • 8.3.1. Calcium Channel Blocker
    • 8.3.2. Gaba Enhancer
    • 8.3.3. Glutamate Inhibitor
    • 8.3.4. Sodium Channel Blocker
  • 8.4. Antipsychotic
    • 8.4.1. Atypical
    • 8.4.2. Typical
  • 8.5. Anxiolytic
    • 8.5.1. Benzodiazepine
    • 8.5.2. Non-Benzodiazepine
  • 8.6. Cns Stimulant
    • 8.6.1. Amphetamines
    • 8.6.2. Methylphenidate
  • 8.7. Hypnotic And Sedative
    • 8.7.1. Barbiturates
    • 8.7.2. Benzodiazepine
    • 8.7.3. Non-Benzodiazepine Hypnotics

9. Central Nervous System Drugs Market, by Dosage Form

  • 9.1. Capsule
    • 9.1.1. Extended-Release Capsule
    • 9.1.2. Standard Capsule
  • 9.2. Injectable Solution
    • 9.2.1. IM
    • 9.2.2. IV
    • 9.2.3. Subcutaneous
  • 9.3. Oral Solution
    • 9.3.1. Suspension
    • 9.3.2. Syrup
  • 9.4. Tablet
    • 9.4.1. Delayed-Release Tablet
    • 9.4.2. Extended-Release Tablet
    • 9.4.3. Standard Tablet
  • 9.5. Transdermal Patch
    • 9.5.1. Matrix Patch
    • 9.5.2. Reservoir Patch

10. Central Nervous System Drugs Market, by Patient Type

  • 10.1. Adult
  • 10.2. Geriatric
  • 10.3. Pediatric

11. Central Nervous System Drugs Market, by Mechanism Of Action

  • 11.1. Cholinergic
  • 11.2. Dopaminergic
  • 11.3. Gabaergic
  • 11.4. Glutamatergic
  • 11.5. Noradrenergic
  • 11.6. Serotonergic

12. Central Nervous System Drugs Market, by Therapeutic Area

  • 12.1. ADHD
  • 12.2. Alzheimer's Disease
  • 12.3. Anxiety
  • 12.4. Depression
  • 12.5. Epilepsy
  • 12.6. Insomnia
  • 12.7. Migraine
  • 12.8. Pain
  • 12.9. Parkinson's Disease
  • 12.10. Schizophrenia

13. Central Nervous System Drugs Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Online Pharmacy
  • 13.3. Retail Pharmacy

14. Central Nervous System Drugs Market, by Prescription Type

  • 14.1. Over The Counter
  • 14.2. Prescription

15. Central Nervous System Drugs Market, by Sales Model

  • 15.1. Branded
  • 15.2. Generic

16. Central Nervous System Drugs Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. Central Nervous System Drugs Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Central Nervous System Drugs Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. United States Central Nervous System Drugs Market

20. China Central Nervous System Drugs Market

21. Competitive Landscape

  • 21.1. Market Concentration Analysis, 2025
    • 21.1.1. Concentration Ratio (CR)
    • 21.1.2. Herfindahl Hirschman Index (HHI)
  • 21.2. Recent Developments & Impact Analysis, 2025
  • 21.3. Product Portfolio Analysis, 2025
  • 21.4. Benchmarking Analysis, 2025
  • 21.5. AbbVie Inc
  • 21.6. Allergan plc
  • 21.7. Amgen Inc
  • 21.8. AstraZeneca plc
  • 21.9. Bayer AG
  • 21.10. Biogen Inc
  • 21.11. Bristol-Myers Squibb Company
  • 21.12. Eli Lilly and Company
  • 21.13. GlaxoSmithKline plc
  • 21.14. H. Lundbeck A/S
  • 21.15. Johnson & Johnson Services, Inc
  • 21.16. Merck & Co., Inc
  • 21.17. Neurocrine Biosciences, Inc
  • 21.18. Novartis AG
  • 21.19. Otsuka Pharmaceutical Co., Ltd
  • 21.20. Pfizer Inc
  • 21.21. Sanofi S.A.
  • 21.22. Takeda Pharmaceutical Company Ltd
  • 21.23. Teva Pharmaceutical Industries Ltd
  • 21.24. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SALES MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 15. UNITED STATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 16. CHINA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-OPIOID ANALGESIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-OPIOID ANALGESIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-OPIOID ANALGESIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY OPIOID ANALGESIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY OPIOID ANALGESIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY OPIOID ANALGESIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIDEPRESSANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIDEPRESSANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIDEPRESSANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GABA ENHANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GABA ENHANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GABA ENHANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GLUTAMATE INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GLUTAMATE INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GLUTAMATE INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SODIUM CHANNEL BLOCKER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SODIUM CHANNEL BLOCKER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SODIUM CHANNEL BLOCKER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ATYPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ATYPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ATYPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TYPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TYPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TYPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BENZODIAZEPINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BENZODIAZEPINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BENZODIAZEPINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-BENZODIAZEPINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-BENZODIAZEPINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-BENZODIAZEPINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY AMPHETAMINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY AMPHETAMINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY AMPHETAMINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY METHYLPHENIDATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY METHYLPHENIDATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY METHYLPHENIDATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BARBITURATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BARBITURATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BARBITURATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BENZODIAZEPINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BENZODIAZEPINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BENZODIAZEPINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-BENZODIAZEPINE HYPNOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-BENZODIAZEPINE HYPNOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-BENZODIAZEPINE HYPNOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY EXTENDED-RELEASE CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY EXTENDED-RELEASE CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY EXTENDED-RELEASE CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STANDARD CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STANDARD CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STANDARD CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY IM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY IM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY IM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY IV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY IV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY IV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUSPENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SYRUP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SYRUP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SYRUP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DELAYED-RELEASE TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DELAYED-RELEASE TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DELAYED-RELEASE TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY EXTENDED-RELEASE TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY EXTENDED-RELEASE TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY EXTENDED-RELEASE TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STANDARD TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STANDARD TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STANDARD TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MATRIX PATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MATRIX PATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MATRIX PATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY RESERVOIR PATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY RESERVOIR PATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY RESERVOIR PATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CHOLINERGIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CHOLINERGIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CHOLINERGIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOPAMINERGIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOPAMINERGIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOPAMINERGIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GABAERGIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GABAERGIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GABAERGIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GLUTAMATERGIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GLUTAMATERGIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GLUTAMATERGIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NORADRENERGIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NORADRENERGIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NORADRENERGIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SEROTONERGIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SEROTONERGIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SEROTONERGIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ADHD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ADHD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ADHD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIETY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIETY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIETY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DEPRESSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DEPRESSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DEPRESSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY EPILEPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INSOMNIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INSOMNIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INSOMNIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MIGRAINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MIGRAINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MIGRAINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SCHIZOPHRENIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SCHIZOPHRENIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SCHIZOPHRENIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY OVER THE COUNTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY OVER THE COUNTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 217. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 218. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 219. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, 2018-2032 (USD MILLION)
  • TABLE 220. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, 2018-2032 (USD MILLION)
  • TABLE 221. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, 2018-2032 (USD MILLION)
  • TABLE 222. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, 2018-2032 (USD MILLION)
  • TABLE 223. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, 2018-2032 (USD MILLION)
  • TABLE 224. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, 2018-2032 (USD MILLION)
  • TABLE 225. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 226. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 227. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 228. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 229. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 230. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, 2018-2032 (USD MILLION)
  • TABLE 231. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 233. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 234. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 235. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, 2018-2032 (USD MILLION)
  • TABLE 240. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, 2018-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, 2018-2032 (USD MILLION)
  • TABLE 242. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, 2018-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, 2018-2032 (USD MILLION)
  • TABLE 244. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, 2018-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 246. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 248. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 250. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, 2018-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 254. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 258. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, 2018-2032 (USD MILLION)
  • TABLE 260. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, 2018-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, 2018-2032 (USD MILLION)
  • TABLE 262. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, 2018-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, 2018-2032 (USD MILLION)
  • TABLE 264. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, 2018-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 266. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 268. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 270. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, 2018-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 274. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA CENTRAL